Effect of Atropine on Denervated Rabbit Ear Blood Vessels
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
GPCR/G Protein
Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33. -
Analytical Reference Standards
Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation. -
Spectrum-Effect Relationships Between High
Jiang et al Tropical Journal of Pharmaceutical Research February 2017; 16 (2): 379-386 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v16i2.17 Original Research Article Spectrum-effect relationships between high performance liquid chromatography fingerprint and analgesic property of Anisodus tanguticus (Maxim) Pascher (Solanaceae) roots Yun-Bin Jiang1, Mei Zhong2, Ming-Xun Hu1, Ling Chen1, Yan Gou3, Juan Zhou3, Pi-E Wu3 and Yu-Ying Ma1* 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, 2Analytical Chemistry Department, West China Frontier Pharmatech Co., Ltd/National Chengdu Center for Safety Evaluation of Drugs, Chengdu 610041, 3Laboratory for Traditional Chinese Medicine and Ethnic Medicine, Sichuan Institute for Food and Drug Control, Chengdu 610079, PR China *For correspondence: Email: [email protected] Received: 10 September 2016 Revised accepted: 11 January 2017 Abstract Purpose: To investigate the spectrum-effect relationships between high performance liquid chromatography with photodiode array detection (HPLC-DAD) fingerprint and analgesic activity of Anisodus tanguticus (Maxim.) Pascher (Solanaceae) (AT) roots. Methods: Analgesic activity of AT roots was evaluated by acetic acid-induced writhing test in mice. Fingerprint of AT roots was established by HPLC-DAD. After oral administration of AT roots extract, intra-gastric contents of caffeoylputrescine, anisodine, fabiatrin, scopolin, scopolamine, anisodamine and atropine in mice were determined by HPLC-DAD. Spectrum-effect relationships between HPLC- DAD fingerprint and analgesic activity were investigated using bivariate correlation analysis. Results: Following treatment with different batches of AT roots extract, acetic acid-induced writhing responses in mice were inhibited significantly (p < 0.05 or 0.01), with inhibitions of 26.62 - 55.13 %, relative to the control group. -
Download Product Insert (PDF)
PRODUCT INFORMATION Anisodamine Item No. 19650 CAS Registry No.: 17659-49-3 Formal Name: αS-(hydroxymethyl)-benzeneacetic acid, 6-hydroxy-8-methyl-8- azabicyclo[3.2.1]oct-3-yl ester O Synonym: 6-hydroxy Hyoscyamine N HO MF: C17H23NO4 O FW: 305.4 Purity: ≥98% OH Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Anisodamine is supplied as a crystalline solid. A stock solution may be made by dissolving the anisodamine in the solvent of choice. Anisodamine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of anisodamine in ethanol and DMF is approximately 25 mg/ml, and approximately 20 mg/ml in DMSO. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of anisodamine can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of anisodamine in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Anisodamine is a natural tropane alkaloid shown to be a weak antagonist of α1-adrenoceptors, blocking WB-4101 and clonidine (Item No. 15949) binding in brain membrane preparations with pKi values of 2.63 and 1.61, respectively.1 Anisodamine also has antioxidant effects that may protect against free radical-induced cellular damage.2 Anisodamine is predominantly found in the roots of A. -
An in Vitro Study on Interaction of Anisodine and Monocrotaline With
Chinese Journal of Natural Chinese Journal of Natural Medicines 2019, 17(7): 04900497 Medicines An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families CHEN Jia-Yin1, Jürgen Brockmöller2, Mladen V. Tzvetkov2, WANG Li-Jun1, CHEN Xi-Jing3* 1 Department of Pharmacy, Peking University Shenzhen Hospital, Shenzhen 518036, China; 2 Institute for Clinical Pharmacology, University Medical Center Göttingen, Georg-August University, Göttingen 37075, Germany; 3 Clinical Pharmacokinetics Lab, China Pharmaceutical University, Nanjing 211198, China; Available online 20 July, 2019 [ABSTRACT] Current study systematically investigated the interaction of two alkaloids, anisodine and monocrotaline, with organic cation transporter OCT1, 2, 3, MATE1 and MATE2-K by using in vitro stably transfected HEK293 cells. Both anisodine and monocro- −1 taline inhibited the OCTs and MATE transporters. The lowest IC50 was 12.9 µmol·L of anisodine on OCT1 and the highest was 1.8 −1 −1 mmol·L of monocrotaline on OCT2. Anisodine was a substrate of OCT2 (Km = 13.3 ± 2.6 µmol·L and Vmax = 286.8 ± 53.6 pmol/mg −1 protein/min). Monocrotaline was determined to be a substrate of both OCT1 (Km = 109.1 ± 17.8 µmol·L , Vmax = 576.5 ± 87.5 −1 pmol/mg protein/min) and OCT2 (Km = 64.7 ± 14.8 µmol·L , Vmax = 180.7 ± 22.0 pmol/mg protein/min), other than OCT3 and MATE transporters. The results indicated that OCT2 may be important for renal elimination of anisodine and OCT1 was responsible for monocrotaline uptake into liver. However neither MATE1 nor MATE2-K could facilitate transcellular transport of anisodine and monocrotaline. -
Toxicology Reference Laboratory
TOXICOLOGY REFERENCE LABORATORY Laboratory User Guide ROOM 708, BLOCK P PRINCESS MARGARET HOSPITAL 2-10 Princess Margaret Hospital Road Lai Chi Kok Tel: 2990 1941 Fax: 2990 1942 http://trl.home Version 6.1 Effective date: 1/July/2014 Contents Contents ..................................................................................................................................................... 2 Introduction ............................................................................................................................................... 4 Staff ............................................................................................................................................................ 5 Honorary Medical Staff .......................................................................................................................... 5 Scientific Staff ........................................................................................................................................ 5 Technical Staff ........................................................................................................................................ 5 Supportive Staff ...................................................................................................................................... 6 How to Make Laboratory Request .......................................................................................................... 7 Instruction for Referring Clinician ........................................................................................................ -
( 12 ) United States Patent
US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp . -
Problems of Drug Dependence 1998: Proceedings of the 60Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc. U.S. Department of Health and Human Services1 • National79 Institutes of Health Problems of Drug Dependence, 1998: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. Virginia Commonwealth University NIDA Research Monograph 179 1998 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 ACKNOWLEDGEMENT The College on Problems of Drug Dependence, Inc., an independent, non-profit organization conducts drug testing and evaluations for academic institutions, government, and industry. This monograph is based on papers or presentations from the 60th Annual Scientific Meeting of the CPDD, held in Scottsdale, Arizona, June 12-17, 1998. In the interest of rapid dissemination, it is published by the National Institute on Drug Abuse in its Research Monograph series as reviewed and submitted by the CPDD. Dr. Louis S. Harris, Department of Pharmacology and Toxicology, Virginia Commonwealth University was the editor of this monograph. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published materials as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. -
Hydroxycinnamic Acid Amides from Scopolia Tangutica Inhibit the Activity of M1 Muscarinic Acetylcholine Receptor in Vitro
Fitoterapia 108 (2016) 9–12 Contents lists available at ScienceDirect Fitoterapia journal homepage: www.elsevier.com/locate/fitote Hydroxycinnamic acid amides from Scopolia tangutica inhibit the activity of M1 muscarinic acetylcholine receptor in vitro Yan Zhang a,⁎,1, Zhen Long b,1,ZhimouGuob, Zhiwei Wang c, Xiuli Zhang b, Richard D. Ye a, Xinmiao Liang b, Olivier Civelli c a School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China b Key laboratory of Separation Science for Analytical Chemistry, Key Lab of Natural Medicine, Liaoning Province, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, People's Republic of China c Department of Pharmacology, University of California, Irvine, CA 92697, United States article info abstract Article history: Scopolia tangutica Maxim (S. tangutica) extracts have been traditionally used as antispasmodic, sedative, and Received 15 September 2015 analgesic agents in Tibet and in the Qinghai province of China. Their active compositions are however poorly Received in revised form 12 November 2015 understood. We have recently isolated five new hydroxycinnamic acid (HCA) amides along with two known Accepted 13 November 2015 HCA amides, one cinnamic acid amide from these extracts. In this study, we evaluate their abilities to inhibit Available online 14 November 2015 carbacol-induced activity of M1 muscarinic acetylcholine receptor along with the crude extracts. Chinese hamster ovary cells stably expressing the recombinant human M1 receptor (CHO-M1 cells) were employed to Keywords: 2+ Scopolia tangutica Maxim evaluate the anticholinergic potentials. Intracellular Ca changes were monitored using the FLIPR system. Hydroxycinnamic acid amides Five HCA amides as well as the crude S. -
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
Known Bioactive Library: Selleck Bioactive 10mM, 3.33mM, 1.11mM ICCB-L Plate (10mM / 3.33mM / ICCB-L Max Solubility Vendor ID Compound Name Pathway Targets Information CAS Number Form URL 1.11mM) Well in DMSO (mM) Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), http://www.selleckchem.c Protein Tyrosine EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 3651 / 3658 / 3665 A03 S1011 Afatinib (BIBW2992) 199 EGFR,HER2 439081-18-2 free base om/products/BIBW2992. Kinase nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib- html resistant L858R-T790M EGFR mutant. Phase 3. http://www.selleckchem.c Deflazacort(Calcort) is a glucocorticoid used as an anti-inflammatory and 3651 / 3658 / 3665 A04 S1888 Deflazacort 199 Others Others 14484-47-0 free base om/products/Deflazacor. immunosuppressant. html http://www.selleckchem.c Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with 3651 / 3658 / 3665 A05 S1198 Irinotecan 17 DNA Damage Topoisomerase 97682-44-5 free base om/products/Irinotecan.ht IC50 of 15.8 μM and 5.17 μM, respectively. ml Enalapril Maleate, the active metabolite of enalapril, competes with http://www.selleckchem.c Endocrinology & 3651 / 3658 / 3665 A06 S1941 Enalapril Maleate 201 RAAS angiotensin I for binding at the angiotensin-converting enzyme, blocking the 76095-16-4 maleate om/products/Enalapril- Hormones conversion of angiotensin I to angiotensin II. maleate(Vasotec).html BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC, respectively. -
Original Article Combined Anisodamine and Probucol
Int J Clin Exp Med 2019;12(4):3250-3260 www.ijcem.com /ISSN:1940-5901/IJCEM0074736 Original Article Combined anisodamine and probucol prevents contrast-induced nephropathy in diabetic rats by inhibiting p38 MAPK and Akt/mTOR/P70S6K signaling pathways Kai Zhao1*, Qiaoying Gao2*, Chunhui Zong2, Yongjian Li1 Departments of 1Cardiology, 2Pharmacology, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin 300100, China. *Equal contributors. Received February 21, 2018; Accepted October 12, 2018; Epub April 15, 2019; Published April 30, 2019 Abstract: Apoptosis is recognized as an important mechanism in contrast-induced nephropathy (CIN). As anisoda- mine and probucol have been found to be renoprotective and anti-apoptotic in multiple kidney injuries, we hypoth- esized that they would prevent CIN. An experimental model of CIN was established in rats. Serum creatinine, blood urea nitrogen, urinary kidney injury molecule-1 (KIM-1), interleukin (IL)-18, and neutrophil gelatinase associated lipocalin (NGAL) levels were measured to evaluate kidney function. Superoxide dismutase (SOD), malondialdehyde (MDA) levels were assessed to discuss the effect of anisodamine and probucol on oxidative stress. The pathological changes of kidney were observed by hematoxylin and eosin (HE) staining and immunohistochemistry (IHC) analysis. Apoptosis was assessed by transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) staining. Phospho-p38 mitoge-activated protein kinase (MAPK) and Akt/mTOR/P70S6K protein expression was assessed by Western blotting. Anisodamine and probucol significantly attenuated the resulting renal dysfunction and renal tubular cell apoptosis. Mechanistically, anisodamine and probucol decreased the expression of MAPK and Akt/ mTOR/P70S6K protein expression. In addition, anisodamine and probucol inhibited Bax protein expression while it upregulated Bcl-2. -
An Overview of the Evidence and Mechanisms of Herb–Drug Interactions
REVIEW ARTICLE published: 30 April 2012 doi: 10.3389/fphar.2012.00069 An overview of the evidence and mechanisms of herb–drug interactions Pius S. Fasinu 1, Patrick J. Bouic 2,3 and Bernd Rosenkranz 1* 1 Division of Pharmacology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa 2 Division of Medical Microbiology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa 3 Synexa Life Sciences, Montague Gardens, Cape Town, South Africa Edited by: Despite the lack of sufficient information on the safety of herbal products, their use as Javed S. Shaikh, Cardiff Research alternative and/or complementary medicine is globally popular. There is also an increasing Consortium: A CAPITA Group Plc Company, India interest in medicinal herbs as precursor for pharmacological actives. Of serious concern is Reviewed by: the concurrent consumption of herbal products and conventional drugs. Herb–drug inter- Sirajudheen Anwar, University of action (HDI) is the single most important clinical consequence of this practice. Using a Messina, Italy structured assessment procedure, the evidence of HDI presents with varying degree of Domenico Criscuolo, Genovax, Italy clinical significance. While the potential for HDI for a number of herbal products is inferred Roger Verbeeck, Université Catholique de Louvain, Belgium from non-human studies, certain HDIs are well established through human studies and *Correspondence: documented case reports. Various mechanisms of pharmacokinetic HDI have been iden- Bernd Rosenkranz, Division of tified and include the alteration in the gastrointestinal functions with consequent effects Pharmacology, Department of on drug absorption; induction and inhibition of metabolic enzymes and transport proteins; Medicine, University of Stellenbosch, and alteration of renal excretion of drugs and their metabolites.